...
首页> 外文期刊>The American heart journal >Long-term outcome of primary angioplasty compared with fibrinolysis across age groups: a Danish Multicenter Randomized Study on Fibrinolytic Therapy Versus Acute Coronary Angioplasty in Acute Myocardial Infarction (DANAMI-2) substudy.
【24h】

Long-term outcome of primary angioplasty compared with fibrinolysis across age groups: a Danish Multicenter Randomized Study on Fibrinolytic Therapy Versus Acute Coronary Angioplasty in Acute Myocardial Infarction (DANAMI-2) substudy.

机译:与不同年龄组的纤维蛋白溶解相比,原发性血管成形术的长期结果:丹麦急性心肌梗死(DANAMI-2)研究中纤维蛋白溶疗法与急性冠状动脉成形术的多中心随机研究。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Primary angioplasty in patients with acute ST-elevation myocardial infarction has been shown to be superior to fibrinolysis. Whether elderly patients have the same long-term benefit from angioplasty, compared with fibrinolysis, as younger patients is unknown. METHODS: The effect of angioplasty versus fibrinolysis was investigated in 1,572 patients from the DANAMI-2 study across age groups. End points were total mortality and a composite end point of death, reinfarction, or disabling stroke. Follow-up was 3 years. RESULTS: Increasing age was associated with mortality (adjusted hazard ratio [HR] 2.45 per 10 year increment, 95% confidence interval [CI] 1.78-3.37, P < .0001) and a higher composite event rate (adjusted HR 1.51, CI 1.26-1.82, P < .0001). The long-term superiority of angioplasty over fibrinolysis on the combined outcome was independent of age: patients aged <56 years (HR 0.73, CI 0.41-1.31); 56 to 65 years (HR 0.83, CI 0.52-1.33); 66 to 75 years (HR 0.71, CI 0.48-1.04); and >75 years (HR 0.83, CI 0.59-1.17) (P = .006 for overall treatment effect and P = .5 for interaction between age and treatment). There was no long-term effect of angioplasty versus fibrinolysis on mortality and no interaction with age (P = .5 and P for interaction = .6). CONCLUSIONS: The long-term effect of primary angioplasty compared with fibrinolysis in patients with ST-elevation myocardial infarction is not affected by age.
机译:背景:急性ST段抬高型心肌梗死患者的原发性血管成形术已被证明优于纤维蛋白溶解。与纤溶相比,老年患者是否具有与纤维蛋白溶解相同的长期长期血管成形术获益尚不清楚。方法:研究了来自DANAMI-2研究的1,572名年龄段患者的血管成形术与纤维蛋白溶解的作用。终点是总死亡率和死亡,再梗塞或中风致残的复合终点。随访时间为3年。结果:年龄的增长与死亡率(调整后的危险比[HR]每10年增加2.45、95%置信区间[CI] 1.78-3.37,P <.0001)和较高的复合事件发生率(调整后的HR 1.51,CI 1.26)相关。 -1.82,P <.0001)。血管成形术优于纤维蛋白溶解对联合治疗的长期优势与年龄无关:年龄<56岁的患者(HR 0.73,CI 0.41-1.31); 56至65岁(HR 0.83,CI 0.52-1.33); 66至75年(HR 0.71,CI 0.48-1.04); > 75岁(HR 0.83,CI 0.59-1.17)(总体治疗效果P = .006,年龄与治疗之间的相互作用P = .5)。血管成形术和纤维蛋白溶解对死亡率没有长期影响,并且与年龄没有相互作用(P = 0.5,相互作用P = 0.6)。结论:对于ST段抬高型心肌梗死患者,与纤维蛋白溶解相比,原发性血管成形术的长期疗效不受年龄的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号